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Rationale: A recent study showed that doctors are excessively pessimistic about the prognosis
in patients with COPD and suggested that a simple tool to predict outcome is needed.
Methods: In a prospective observational study, 3343 patients with an FEV1< 80% of the pre-
dicted value and FEV1/FVC< 70% were selected from a clinical network of patients screened
for COPD in Tayside, Scotland. Data were collected during annual visits on demography,
spirometry, smoking history, medical research council (MRC) dyspnoea scale, body mass index
(BMI) and other variables. The main outcome measures were hospitalisations and death
secondary to COPD. A proportional hazard model was used to identify significant risk factors.
Results: Increasing age, low BMI, worsening MRC dyspnoea score, decreased FEV1, and prior
respiratory or cardiovascular admission hospitalisation were predictors of poor outcome. Influ-
enza vaccination was protective.
Conclusion: We have developed a model that estimates the risk of respiratory hospitalisation
and death in patients with COPD.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
COPD is a major cause of mortality and morbidity in the UK,
accounting for over one million in-patient bed days each
year.1 This imposes a significant burden on health services.2,3) 1382 660111.
t (S. Schembri).
9 Elsevier Ltd. All rights reservedIn 2002, 23,878 people in the UK died fromCOPD as a result of
smoking.4 Previous studies of predictors of COPD hospital-
isation andmortality have consistently identified risk factors
including; smoking, FEV1, hypercapnia, hypoxia, oxygen
therapy, co-morbidities, age, low body weight, hospital
admission, use of oral steroids, depression, poor perfor-
mance status and lack of outdoor activity.5e14
A recent study and editorial published in the BMJ showed
that doctors are excessively pessimistic about the prognosis.
1462 S. Schembri et al.in patients with COPD16,17 and a simple tool to predict
outcome is overdue. We used prospectively collected data
from a population with COPD to find predictors of respira-
tory hospitalisation and death and build a predictive model
that could have clinical utility.
Methods
Study population
Since 2001, general practitioners (GPs) in Tayside have
been invited to refer patients in whom they suspect chronic
obstructive pulmonary disease (COPD) for screening
spirometry. Trained COPD nurses using a spriometer in each
practice carried out spirometry in the GPs practice. COPD
nurses receive structured training in order to obtain stan-
dardized results.
Those patients in whom COPD is diagnosed are then
invited to participate in a structured management pro-
gramme called Tayside Allergy and Respiratory Disease
Information System (TARDIS). We visited patients annually
andmeasured the variables shown inTable 1. If patientswere
housebound they were visited at home annually and this was
also recorded in the database. A six-minute walk test was
carried out in patients undergoing pulmonary rehabilitation.
We defined COPD as an FEV1< 80% of the predicted
value (greatest of pre- and post-bronchodilator values) and
FEV1/FVC< 70%. Patients entered the study cohort when
they first met both of these criteria. From this index date
patients were followed up annually and the informationTable 1 Variables recorded in the Tayside Allergy and
Respiratory Disease Information System (TARDIS).
Demographics Gender
Age
Deprivation score
Smoking status and history
Body mass index (BMI)
Severity of COPD
and quality of
life
Respiratory symptoms
Spirometry: pre- and
post-bronchodilator FEV1
and FVC measured in litres
and expressed as a percentage
of their predicted value
MRC dyspnoea score
Mobility
Airways questionnaire 20 (AQ20)
Hospital anxiety and depression
scores (HADS)
History of
treatment
Past medical history
Oxygen use
Inhaler technique at time of diagnosis
Oral or intravenous steroids
(number of courses);
Antibiotics use (number of courses),
Vaccination status
The AQ20 is a questionnaire developed to measure and quantify
disturbances in the health-related quality of life of patients
with asthma or chronic obstructive pulmonary disease (COPD).15listed in Table 1, together with the number of hospital
admissions, were recorded each year.
Ethics approval reference 06/S1402/27 was obtained
from the Tayside committee on medical ethics.
Outcome
The primary outcome was hospitalisation or death due to
COPD. Hospitalisations were obtained from the Scottish
Morbidity Records (SMR1), which contain all records of hos-
pitalisation and is held in the Medicines Monitoring Unit18
(MEMO). Cause of death was obtained from the General
Registry Office (GRO) for Scotland. The codes used to identify
events are listed in the Appendix. All records were linked
using eachpatient’s uniqueCommunityHealth Index number.
Statistical methods
The time to hospitalisation or death was determined for
each patients from their index date. The time to event was
modelled using proportional hazard models with a Weibull
distribution.19 All the continuous covariates were cat-
egorised and non-significant covariates were dropped from
the full model by a process of backward elimination.
A reducedmodel, including only the statistically significant
predictors of each outcome (p< 0.05), was used to calculate
a risk score. Outcomesweremodelledusing this score alone as
a predictor. The cumulative risks of an event at 1, 2, 3, 4 and 5
yearswere plotted against the score to illustrate the observed
range of risks among patients in this study population.
We carried out sensitivity analyses which eliminated
predictors with large number of missing values, and patients
with any missing values for the statistically significant
predictors. We present analyses based on patients with no
missing values for the significant predictor variables.
Results
A total of 6945 individuals were screened between January
2001 and December 2005. We excluded 38 subjects who
transferred out of Tayside during the study period. The
3343 patients who fulfilled the inclusion criteria entered
the study cohort. The median follow-up was 1.9 years, the
interquartile range was 1.0e2.9 years and the longest
follow-up period was 5.3 years.
Table 2 shows the baseline characteristics of the study
cohort. It also shows the categorisation of the continuous
covariates used in the statistical models.
Hospitalisation or death
There were 801 primary events (first hospitalisation or
deaths). A total of 550 deaths were recorded during the
study period and 182 of these were secondary to respiratory
causes. During the study period, 715 patients were hospi-
talised with respiratory causes; 387 (54%) were hospitalised
once, 160 (22%) were hospitalised twice and 168 (24%) were
hospitalised more than twice.
Estimates of hazard ratios for the statistically significant
predictors of respiratory hospitalisation or respiratory death
are shown in Fig. 1. We found that increasing age, low BMI,
Table 2 Baseline distributions of covariates in the study
cohort.
Total patients N %
3343 100.0
Gender Women 1657 49.6
Men 1686 50.4
Age group (years) <50 226 6.8
50e59 571 17.1
60e69 1057 31.6
70e79 1,112 33.3
80 377 11.2
Smoking status Current 1734 51.9
Not 1609 48.1
Pack years Unknown 299 8.9
Never smoked 16 0.5
<20 333 10.0
20e29 445 13.3
30e39 603 18.0
40 1647 49.3
Body mass index (kg/m2) Unknown 129 3.9
<18.5 212 6.3
18.5e<25 1305 39.0
25e<30 1078 32.3
30e<35 425 12.7
>35 194 5.8
Cough Unknown 51 1.5
None 689 20.6
Daily 2156 64.5
Weekly 340 10.2
Monthly 107 3.2
Wheeze Unknown 151 4.5
None 270 8.1
Day 1685 50.4
Night 279 8.3
Day & Night 958 28.7
Wakes with symptoms Unknown 166 5.0
No 2246 67.2
Yes 931 27.8
Sputum Unknown 58 1.7
None 1026 30.7
White 1589 47.5
Yellow 300 9.0
Green 198 5.9
Dirty 172 5.2
Sputum volume Unknown 88 2.6
None 1001 29.9
15 ml 1477 44.2
1/2 cup 674 20.2
>1/2 cup 103 3.1
Blood in sputum Unknown 197 5.9
No 3079 92.1
Yes 67 2.0
Base FEV1/FVC (%) <30 75 2.2
30e<50 1117 33.4
50e<70 2151 64.4
Base/Pred FEV1 (%) <30 229 6.9
30e<50 981 29.3
50e<80 2133 63.8
Table 2 (continued ).
Total patients N %
3343 100.0
Dyspnoea score Unknown 77 2.3
1 373 11.2
2 1299 38.8
3 764 22.8
4 637 19.1
5 193 5.8
Housebound No 3207 95.9
Yes 136 4.1
Prior respiratory admission No 2703 80.8
Yes 640 19.2
Prior CV admission No 2739 81.9
Yes 604 18.1
History of oxygen use No 3290 98.4
Yes 53 1.6
Steroid courses Unknown 117 3.5
0 2249 67.3
1 486 14.6
2 225 6.7
3 98 2.9
4þ 168 5.0
Antibiotic courses Unknown 122 3.6
0 1285 38.4
1 704 21.1
2 493 14.8
3 278 8.3
4þ 461 13.8
Vaccination Influenza 2027 60.6
Pneumonia 963 28.8
A predictive model of hospitalisation and death 1463high MRC dyspnoea scores, decreased FEV1, and prior respi-
ratory or cardiovascular hospitalisationwere associatedwith
poor outcomes. Influenza vaccination was protective.
Risk scores for these predictors were defined as 3 times
the logarithm of the hazard ratios, rounded to the nearest
integer and these are shown in Table 3. Fig. 2 shows the
estimated cumulative risk at 1, 2, 3, 4 and 5 years as
a function of patients’ total scores. The range of scores in
our study population was 7e14, and the range of one year
risks was <1e87%.
Discussion
This study suggests that simple tool can be developed to
estimate the risk of respiratory morbidity and mortality in
patients with COPD. Increasing age, FEV1, poor MRC dysp-
noea score, and prior respiratory hospitalisations have been
previously documented as predictors of poor outcome5e11,
these feature in our model. COPD has been shown to be
a predictor of cardiovascular admission.20 Our cohort shows
that the inverse association also exists. Influenza vaccina-
tion but not pneumococcal vaccination was protective
against death or admission.
We also confirmed the association between low body
mass and poor prognosis and mortality in patients with
established COPD which has been reported elsewhere.12e14
A low BMI may represent a marker of increased energy
Figure 1 Hazard ratio (95% CI).
1464 S. Schembri et al.expenditure due to dyspnoea and this may explain its
association with poor outcome. Alternatively, it may be
a marker of co-morbidity. The association between
increased BMI and better outcomes has been documented
before, it has been postulated that obesity might itself
result in a decreased FEV1 resulting in obese patients being
spirometrically classified as having more severe COPD
therefore gaining a survival advantage.14
The risk calculator can be used to guide physicians’ time to
interventions that could possibly change outcome. Thus
ensuring that COPD patients are vaccinated against influenza,
giving smoking cessation advice as this is the only intervention
proven to slow the rate of decline in FEV1 and giving increased
attention to the calorific intake of patients with a low BMI.
Currently the BODE index21 is commonly used to predict
outcome in COPD. BODE is amultidimensional grading system
using four factors topredict the risk of deathbetter thanFEV1
alone: the body mass index (B), the degree of airflow
obstruction (O) and functional dyspnoea (D), and exercisecapacity (E) as assessed by the six-minute walk test. While
BODE and our model have some similarities, both use BMI,
FEV1 and MRC dyspnoea score, our study has some advan-
tages. It is larger (3173 vs 832 patients) and it has a longer
follow-up period (median 1.9 years vs 1 yr). Furthermore
49.5% of our cohort were female, whereas women were not
well represented in the BODE study. The BODE study had the
advantage of recruiting from more than one country. Unlike
the BODE study, we could not include the six-minute walk
test in our analysis because our population was a community
one where exercise tests are less commonly carried out. This
test was only carried out on more symptomatic patients who
were referred for pulmonary rehabilitation.
The strengths of the present study are that data were
collected prospectively from an unselected community
population of COPD patients. This increases the likelihood
that the predictive model will be applicable to other COPD
populations. In addition, the outcomes were ascertained
fully by record linkage and direct patient interview. Such
Table 3 Scores derived from the significant predictors for
respiratory hospitalisation or respiratory death.
Risk factor Level Score
Age group Under 50 0
50e59 0
60e69 1
70e79 2
80 plus 3
Body mass index Underweight 1
Healthy 0
Overweight 1
Obese 1
Very obese 1
MRC Dyspnoea score 1 0
2 2
3 3
4 4
5 4
Baseline/predicted FEV1 <30 2
30e<50 1
50e<80 0
Prior respiratory admission No 0
Yes 3
Prior CV admission No 0
Yes 1
Influenza vaccination No 1
Yes 0
A predictive model of hospitalisation and death 1465record linkage augmented by field work represents excel-
lent quality data that are likely to be reliable.
Some data were missing from the dataset: 129 patients
(3.9%) had no BMI measurement; 77 (2.3%) had no dyspnoea
score recorded; and 299 patients (8.9%) had an unknown
smoking history. However, subjects entered the cohort100
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Figure 2 Calculated cumafter being referred for COPD screening by their general
practitioner so it is likely that most patients will have some
smoking history. The reasons for the missing data are
unknown although it is possible that BMI could not be
measured in some patients due to their poor mobility.
Finally, these data were generated from a population of
predominantly white Caucasians living in Scotland and
these results may not be applicable to other racial groups.
However, the consistency between our findings and those of
previous studies suggest that our results are likely to be
generalisable across the populations represented in these
studies collectively.
Conclusion
We have produced a risk model for respiratory hospital-
isation or death based on a limited number of measure-
ments that are routinely recorded for patients with COPD.
It predicts a wide range of short-term risks in our study
population, but at present we have insufficient follow-up to
estimate long-term risks reliably.
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ICD10 codes for respiratory outcomes
Influenza and
pneumonia
Influenza due to identified
influenza virus
Influenza with p
Influenza with o
influenza virus i
Influenza with o
Influenza, virus not
identified
Influenza with p
Influenza with o
Influenza with o
Viral pneumonia, not
elsewhere classified
Adenoviral pneu
Respiratory sync
Parainfluenza vi
Other viral pneu
Viral pneumonia
Bacterial pneumonia, not
elsewhere classified
Pneumonia due
Pneumonia due
Pneumonia due
Pneumonia due
Pneumonia due
Pneumonia due
Pneumonia due
Pneumonia due
Other bacterial
Bacterial pneum
Pneumonia due to other
infectious organisms, not
elsewhere classified
Chlamydial pne
Pneumonia due
Pneumonia in diseases
classified elsewhere
Pneumonia in b
Pneumonia in vi
Pneumonia in m
Pneumonia in p
Pneumonia in o
Pneumonia, organism
unspecified
Bronchopneumo
Lobar pneumon
Hypostatic pneu
Other pneumon
Pneumonia, uns
Chronic lower
respiratory
diseases
Other chronic obstructive
pulmonary disease
Chronic obstruc
lower respirator
Chronic obstruc
exacerbation, u
Other specified
Chronic obstruc
Asthma Predominantly a
Nonallergic asth
Mixed asthma
Asthma, unspecgrants from GlaxoSmithKline, Aventis, Novartis, AstraZeneca,
BMS, Bohringer Ingelheim, Pfizer and Novartis. TMM has been
paid Consulting fees by Pfizer, Novartis, Kaiser Permanante,
Quintiles,Takeda,AstraZeneca,SankyoRecordati andSpeedel.neumonia, influenza virus identified J10.0
ther respiratory manifestations,
dentified
J10.1
ther manifestations, influenza virus identified J10.8
neumonia, virus not identified J11.0
ther respiratory manifestations, virus not identified J11.1
ther manifestations, virus not identified J11.8
monia J12.0
ytial virus pneumonia J12.1
rus pneumonia J12.2
monia J12.8
, unspecified J12.9
to Klebsiella pneumoniae J15.0
to Pseudomonas J15.1
to staphylococcus J15.2
to streptococcus, group B J15.3
to other streptococci J15.4
to Escherichia coli J15.5
to other aerobic Gram-negative bacteria J15.6
to Mycoplasma pneumoniae J15.7
pneumonia J15.8
onia, unspecified J15.9
umonia J16.0
to other specified infectious organisms J16.8
acterial diseases classified elsewhere J17.0
ral diseases classified elsewhere J17.1
ycoses J17.2
arasitic diseases J17.3
ther diseases classified elsewhere J17.8
nia, unspecified J18.0
ia, unspecified J18.1
monia, unspecified J18.2
ia, organism unspecified J18.8
pecified J18.9
tive pulmonary disease with acute
y infection
J44.0
tive pulmonary disease with acute
nspecified
J44.1
chronic obstructive pulmonary disease J44.8
tive pulmonary disease, unspecified J44.9
llergic asthma J45.0
ma J45.1
J45.8
ified J45.9
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